Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation
Cell Biochemistry and Function · 2025
DOI: 10.1002/cbf.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2025. Verfasst von Rong Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Deparment of Laboratory Animal Science, Kunming Medical University, Kunming, Yunnan, P. R. China. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Diabetes Mellitus, Type 2, Glycogen Synthase Kinase 3 beta, Osteoblasts. Die Arbeit nennt 43 Literaturangaben. Gefördert von: The study was supported by the National Natural Science Foundation of China (No. 82460164); Applied Basic Research Key Project of Yunnan Province (No. 202201AY….
Themen: Diabetes mellitus
Abstract (Originalsprache)
Osteoking (OK) exerts bone formation‐promoting effects on menopausal osteoporosis and osteoporotic fractures. However, it remains to be determined whether OK ameliorates type 2 diabetic osteoporosis (T2DOP) via PI3K/AKT/GSK‐3β pathway activation. Thus, the T2DOP animal model was established in db/db mice in this study. Microcomputed tomography (micro‐CT) analysis revealed that OK significantly increased bone strength, improved bone metabolism, and promoted bone formation. GS and p‐GSK‐3β expression levels were increased in OK group as compared with db/db group by western blot analysis. IL‐6, IL‐17A, IFN‐γ, TNF‐α, and IL‐1β were lower levels in the OK group compared to the db/db group, nevertheless, the IL‐10 level was significantly higher. Furthermore, an in vitro cells model was constructed by stimulating with high glucose (HG, 30 mM). ALP protein was significantly elevated in the OK treatment group. Administration of OK at 0.288 mg/mL significantly increased p‐AKT/AKT expression, while, combined with LY294002, an inhibitor of PI3K, OK significantly reduced the expression levels of p‐PI3K/PI3K, p‐AKT/AKT, and p‐GSK‐3β/GSK‐3β. In conclusion, this study reveals OK exhibits efficacy against T2DOP in db/db mice by promoting osteogenesis of preosteoblast MC3T3‐E1 cells through PI3K/AKT/GSK‐3β pathway regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Deparment of Laboratory Animal Science, Kunming Medical University, Kunming, Yunnan, P. R. China.
- Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, P. R. China.
- School of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan, P. R. China.
ORCID-Profile: Hong Zheng
Förderung
- The study was supported by the National Natural Science Foundation of China (No. 82460164); Applied Basic Research Key Project of Yunnan Province (No. 202201AY…
Zitieren
APA
Li, R., Lu, J., Wang, P., Zhao, Y., Yang, Y., Jiao, J., Qian, Z., Wang, L., & Zheng, H. (2025). Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70108
Vancouver
Li R, Lu J, Wang P, Zhao Y, Yang Y, Jiao J, et al. Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70108
BibTeX
@article{Li2025,
author = {Li, Rong and Lu, Jiangli and Wang, Peijin and Zhao, Yulan and Yang, Yi and Jiao, Jianlin and Qian, Zhongyi and Wang, Limei and Zheng, Hong},
title = {Osteoking Ameliorates Type 2 Diabetes Osteoporosis by Enhancing Osteoblast Differentiation via PI3K/AKT/GSK‐3β Pathway Activation},
journal = {Cell Biochemistry and Function},
year = {2025},
doi = {10.1002/cbf.70108}
}
EUVIMED